Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1

(2017) Xuewei Cheng et al.   Acta Pharmaceutica Sinica B

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3

(2015) Rongrong Jiang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases

(2015) Nan Zhang et al.   Scientific Reports

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors

(2013) Colin F Spraggs et al.   PHARMACOGENOMICS

Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases

(2013) Limei Ai et al.   XENOBIOTICA

Intestinal Absorption and Presystemic Elimination of Various Chemical Constituents Present in GBE50 Extract, a Standardized Extract of Ginkgo biloba Leaves

(2012) Li Li et al.   CURRENT DRUG METABOLISM

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

(2012) Suneet Shukla et al.   DRUG RESISTANCE UPDATES

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors

(2009) Ferenc Zsila et al.   CURRENT MEDICINAL CHEMISTRY

Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases

(2009) Y. Liu et al.   DRUG METABOLISM AND DISPOSITION

Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu-tang across human intestinal Caco-2 cell monolayers1

(2008) Jie-yu DAI et al.   ACTA PHARMACOLOGICA SINICA

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

(2008) Regina I. Jakacki et al.   JOURNAL OF CLINICAL ONCOLOGY